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Abstract
Background: Heme oxygenase-1 is an inducible cytoprotective enzyme which handles oxidative
stress by generating anti-oxidant bilirubin and vasodilating carbon monoxide. A (GT)n dinucleotide
repeat and a -413A>T single nucleotide polymorphism have been reported in the promoter region
of HMOX1 to both influence the occurrence of coronary artery disease and myocardial infarction.
We sought to validate these observations in persons scheduled for coronary angiography.
Methods: We included 3219 subjects in the current analysis, 2526 with CAD including a subgroup
of CAD and MI (n = 1339) and 693 controls. Coronary status was determined by coronary
angiography. Risk factors and biochemical parameters (bilirubin, iron, LDL-C, HDL-C, and
triglycerides) were determined by standard procedures. The dinucleotide repeat was analysed by
PCR and subsequent sizing by capillary electrophoresis, the -413A>T polymorphism by PCR and
RFLP.
Results: In the LURIC study the allele frequency for the -413A>T polymorphism is A = 0,589 and
T = 0,411. The (GT)n repeats spread between 14 and 39 repeats with 22 (19.9%) and 29 (47.1%)
as the two most common alleles. We found neither an association of the genotypes or allelic
frequencies with any of the biochemical parameters nor with CAD or previous MI.
Conclusion: Although an association of these polymorphisms with the appearance of CAD and
MI have been published before, our results strongly argue against a relevant role of the (GT)n repeat
or the -413A>T SNP in the HMOX1 promoter in CAD or MI.
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Background
Low-grade inflammation and oxidation are important
mechanisms involved in the complex pathological proc-
ess of atherogenesis [1]. Several cardiovascular risk factors,
such as smoking, type 2 diabetes, hypertension, and dysl-
ipidemia, increase the production of reactive oxygen spe-
cies (ROS) in the arterial wall. In response to oxidative
stress the expression of endogenous stress proteins includ-
ing heme oxygenase (HO) is increased. HO is a rate-limit-
ing enzyme in the degradation of heme to biliverdin
releasing equimolar quantities of free iron and carbon
monoxide, a potent anti-apoptotic and proliferation pro-
moting compound [2]. The reduction of biliverdin by
biliverdin reductase leads to the generation of bilirubin, a
potent endogenous antioxidant [3,4]. Recently, it could
be shown that bilirubin has an antiproliferative effect on
vascular smooth muscle cells, too [5].
In humans two isoforms of heme oxygenase, HO-1 and
HO-2, have been described. HO-1 is the inducible iso-
form, which is up-regulated by various exogenous stimuli,
such as oxidative stress, hypoxia, or its own substrate
heme [6,7]. The enzyme is expressed in atherosclerotic
lesions, vascular smooth muscle cells, endothelial cells,
and several other tissues [8]. There are several lines of evi-
dence that HO-1 has protective properties in the cardio-
vascular system. HO-1 provides protection against cellular
proliferation and lesion formation after arterial injury [9].
In rats vascular remodelling following balloon injury was
beneficially influenced after induction of HO-1 [10]. In
addition, thrombus formation was suppressed by vascular
HO-1 [11] and HO-1 inhibited vascular smooth muscle
cell proliferation in vitro [12]. Overexpression of HO-1 in
endothelial cells has not only improved the ability of
these cells to resist oxidative stress but also enhances cell
growth [13]. Thus, the up regulation of HO-1 in athero-
sclerotic lesions might be a physiological reaction to pre-
vent atherosclerotic progression [14].
Two different polymorphisms in the HMOX1 promoter, a
(GT) dinucleotide repeat and the -413A>T (rs2071746)
single nucleotide polymorphism (SNP) are thought to be
involved in the pathogenesis of cardiovascular disease by
modulating the expression of HO-1 [15-24].
We investigated whether these variants are associated with
angiographic coronary artery disease (CAD), myocardial
infarction (MI), or mortality in a large cohort of individu-
als who had previously undergone coronary angiography.
Methods
Study design and participants
The  Ludwigshafen  Risk and Cardiovascular Health
(LURIC) study includes consecutive white patients hospi-
talized for coronary angiography between July 1997 and
January 2000. The study was approved by the ethics
review committee at the "Landesärztekammer Rheinland-
Pfalz" (Mainz, Germany). Written informed consent was
obtained from each of the participants.
A detailed description of LURIC has been published [25].
Diabetes mellitus was diagnosed according to the criteria
of the American Diabetes Association (ADA) [26]. Fur-
ther, individuals with a history of diabetes or treatment
with oral antidiabetics or insulin were considered dia-
betic. CAD has been defined angiographically using the
maximum luminal narrowing estimated by visual analy-
sis. Clinically relevant CAD was defined as the presence of
a visible luminal narrowing (≥ 20% stenosis) in at least
one of 15 coronary segments according to a classification
of the American Heart Association [27]. We also provi-
sionally defined CAD as the presence of at least one sten-
osis of 50 percent or more, again classifying individuals
with stenosis less than 20 percent as controls. Previous MI
was diagnosed if there was a conclusive positive history of
myocardial infarction or if patients presented ST eleva-
tion. Hypertension was diagnosed if the systolic and/or
diastolic blood pressure exceeded 140 and/or 90 mm Hg
or if there was a history of hypertension, evident through
the use of antihypertensive drugs. Individuals with either
HDL cholesterol (HDL-C) <40 mg/dl or LDL cholesterol
(LDL-C) >160 mg/dl or triglycerides >200 mg/dl were
considered dyslipidemic.
We included 3219 patients in this study; all of them
underwent coronary angiography. To rule out racial differ-
ences as a confounding factor the LURIC study was
designed to recruit probands with German ancestry only.
We did not include family members of the patients for
this study.
Information on vital status was obtained from local per-
son registries. No patients were lost to follow-up.
Amongst the subjects included in this examination, 752
deaths (23.4%) had occurred during a median observa-
tion time of 7.97 years. Cardiovascular death (n = 473)
included the following categories: sudden death, fatal
myocardial infarction, death due to congestive heart fail-
ure, death immediately following intervention to treat
CAD, fatal stroke and other causes of death due to CAD.
All clinical assessments were made blinded to the knowl-
edge of HMOX1 genotype.
Laboratory Procedures
Fasting blood samples were obtained by venipuncture in
the early morning. Levels of cholesterol, triglycerides,
bilirubin, iron, transferrin, and ferritin were determined
with common laboratory procedures [25]. LDL-C and
HDL-C were measured after separating lipoproteins with
a combined ultracentrifugation-precipitation method.BMC Medical Genetics 2009, 10:36 http://www.biomedcentral.com/1471-2350/10/36
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Analysis of the HO-1 promoter variants
Genomic DNA was prepared from EDTA-anticoagulated
peripheral blood by using a standard salting-out proce-
dure. Genotypes of the -413A>T polymorphism were
determined using polymerase chain reaction with a mis-
matched 5' primer to obtain an allele specific restriction
site for HindIII in the amplicon (sense 5'-gtt cct gat gtt gcc
cac caagct-3'; reverse 5'-tct gag aag ctg cag gct ctg-3'). In
case of the A genotype a fragment of 163 bp and in case of
the T genotype two fragments of 140 bp + 23 bp were
obtained. To validate the method three samples of each
genotype were sequenced; as internal control 184 DNA
samples, blinded distributed within the samples, were
genotyped twice. To confirm genotype assignment, the
restriction fragments were analyzed independently by two
scientists on two separate occasions. The results were
scored blinded as to case-control status.
The microsatellite polymorphism was amplified accord-
ing to the protocol described by Kaneda et al. [18] and
analyzed on a MegaBASE500 sequencer. As controls two
cloned alleles (22 & 30 repeats) were run in parallel. The
respective sizes of the (GT)n repeats were each calculated
using Genetic Profiler software (Amersham).
Statistics
Clinical and anthropometric characteristics were com-
pared between CAD patients and controls by analysis of
variance (ANOVA) or logistic regression. Covariable
adjustments were carried out as indicated. Associations
between categorical variables were examined by chi-
square testing or logistic regression analysis. The frequen-
cies of the HMOX1 alleles and genotypes in CAD+ and
CAD- as well as in MI+ and MI- subjects were obtained by
direct count and the deviation from Hardy-Weinberg
equilibrium was examined by the chi-square test. In mod-
els assuming a co-dominant (additive) effect of the A-
allele of the HMOX1 gene, the genotypes AA, AT and TT
were coded as 0, 1, and 2, respectively. Genotypes were
either treated as interval-scaled or categorical variables,
the AA genotype being considered as the reference cate-
gory in the latter case. When assuming a dominant effect,
genotype TT was coded as 0, and AT and AA combined as
1, whereas assuming a recessive effect, genotypes TT and
AT were coded as 0, and AA as 1. In a similar way the
repeat classes (cut off S<25, L= 25, or S<27, L= 27, respec-
tively) and both haplotypes (22-T, 29-A) were analyzed.
To examine the relationship of the genotypes with total
mortality and mortality from cardiovascular causes, we
calculated hazard ratios and 95 percent confidence inter-
vals (95% CI) using the Cox proportional hazards model.
The criterion for statistical significance was p < 0.05. The
SPSS statistical package (SPSS Inc., Chicago, IL, USA, ver-
sion 15.0 for Windows XP) was used for all statistical anal-
yses.
Results
Study participants – Baseline Characteristics
We included 3219 subjects in the current analysis. 693
were control subjects without CAD, 2526 were diagnosed
CAD-positive by angiography and from these 1339 had
suffered and survived a MI in the past. Compared to the
control group, patients with CAD and with a former MI
were significantly older, current or past smoker and type 2
diabetes were more prevalent (Table 1). Systemic Hyper-
tension was only significantly higher in the CAD group
compared to the control group, but not in the CAD and
MI group. No significant differences were found for BMI.
CAD and CAD plus MI patients had higher fasting glu-
cose, lower HDL-C, lower bilirubin serum levels and
lower iron serum concentrations. After adjustment for use
of lipid lowering drugs CAD patients had – compared to
the control group – higher LDL-C (p < 0.002) and higher
triglycerides (p < 0.012). No significant difference was
found for the two last mentioned parameters for the CAD
plus MI group (Table 1).
With regard to the tested biochemical parameters there
were no significant differences between the CAD and the
CAD plus MI patients.
-413A>T polymorphism
The overall allelic distribution in the LURIC study is A =
0,589 and T = 0,411. The genotypes were in Hardy-Wein-
berg equilibrium in both the CAD and the control group.
There was no significant difference in the frequency of
genotypes between CAD patients and controls (Table 2).
Using logistic regression analysis to examine a possible
association between the HMOX1  polymorphism and
CAD we found no evidence for this association, regardless
of whether or not we adjusted for conventional cardiovas-
cular risk factors like age, gender, smoking, type 2 diabe-
tes, dyslipidemia and hypertension (Table 3). Very similar
results were obtained when we compared the -413A>T
genotypes in patients with previous MI versus controls or
CAD patients without MI (data not shown).
(GT)n repeat
In the study group the (GT)n repeats spread between 14
and 39 repeats with 22 and 29 as the two most common
alleles, which represents a shift of minus one repeat in
comparison to published data. Although we used cloned
and sequenced alleles as controls we cannot exclude that
this is a methodical mistake.
According to the classification of Funk et al. [28], we chose
a cut-off at 25 and in a second model according to Kaneda
et al. [18] a cut-off at 27 repeats: class S (small) < 25 or 27
repeats and class L (large) ≥ 25 or 27 repeats, respectively.
Similar to the results presented for the -413A>T polymor-BMC Medical Genetics 2009, 10:36 http://www.biomedcentral.com/1471-2350/10/36
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phism we found no significant differences in the distribu-
tion of the repeats (Table 2). In a logistic regression
analysis no association could be found with CAD (Table
3) or MI (data not shown), irrespective of the chosen cut-
off.
Chen et al. [17] described an association of the L allele (≥
32 repeats) with CAD in type 2 diabetic patients. In a sub-
group analysis of type 2 diabetic patients (n = 1035) we
could not confirm this observation, the L alleles (≥ 32
repeats) were evenly distributed between cases and con-
trols (allele frequency 5.2% versus 5.5%, p = 0.619).
Haplotypes
The small repeats, e.g. 22 – the most frequent ones in the
class S alleles – are associated with the T allele, while the
large repeats, e.g. 29, with the exception of very large
repeats (34–38), are associated with the A allele (pairwise
LD r2 = 0,63). Analysis of the two most common haplo-
types, 22-T (19.9%) and 29-A (47.1%), did not generate
new information with regard to cardiovascular disease;
there was still no association with CAD or MI (data not
shown).
We obtained similar results by using a stenosis of at least
50% in the coronary segments as the criterion for CAD in
all of the above mentioned analysis (data not shown).
HMOX1 variants, all cause and cardiovascular mortality
Amongst the 3219 subjects included in this examination,
752 deaths (23.4%) had occurred during a median obser-
vation time of 7.97 years, from which 473 (14.7%) died
from cardiovascular causes. Regardless whether or not we
adjusted for age and gender, there was neither an associa-
tion of the genetic markers of HMOX1  with mortality
from all causes nor with cardiovascular mortality (Table
4).
HMOX1 variants and biochemical parameters
Products of the enzymatic action of HO-1 are iron and
biliverdin, which in turn is converted to bilirubin. If pro-
moter variants influence the systemic expression of HO-1
Table 1: Baseline characteristics and risk factors in patients with angiographically proven CAD, and previous MI as compared to 
controls without CAD.
Controls CAD p CAD and MI p
Male (n = 360) (n = 1891) (n = 1060)
Female (n = 333) (n = 635) (n = 279)
Age (years) means ± SD Male 55 ± 12 63 ± 10 63 ± 10
Female 62 ± 10 66 ± 10 <0.0011 65 ± 10 <0.0011
Body mass index (kg/m2) means ± SD Male 27 ± 4 28 ± 4 27 ± 4
Female 27 ± 5 27 ± 5 n.s.2 27 ± 5 n.s.2
Smoker (former and current) Male 239 (66%) 1487 (78%) 867 (82%)
Female 100 (30%) 253 (39%) <0.0014 145 (51%) <0.0014
Diabetes mellitus Male 63 (17%) 653 (34%) 374 (35%)
Female 66 (20%) 253 (39%) <0.0014 120 (42%) <0.0014
Systemic Hypertension Male 212 (58%) 1399 (74%) 736 (69%)
Female 228 (69%) 519 (81%) 0.0024 220(77%) n.s.4
Fasting blood glucose (mmol/L) means ± SD Male 5,89 ± 1,67 6,39 ± 1,89 6,34 ± 1,83
Female 5,78 ± 1,34 6,6 ± 2,44 <0.0012 6,67 ± 2,5 <0.0012
LDL-C(mmol/L) means ± SD Male 3,02 ± 0,8 2,92 ± 0,85 2,84 ± 0,83
Female 3,2 ± 0,8 3,2 ± 1,01 0.0023 3,05 ± 1,01 n.s.3
HDL-C (mmol/L) means ± SD Male 1,03 ± 0,28 0,93 ± 0,23 0,9 ± 0,23
Female 1,19 ± 0,31 1,09 ± 0,28 <0.0013 1,03 ± 0,28 <0.0013
Bilirubin (μmol/L) means ± SD Male 13,17 ± 7,53 11,46 ± 6,33 10.95 ± 5.82
Female 9.58 ± 4,62 8,89 ± 6,16 <0.0012 8,38 ± 4,10 <0.0012
Iron (μmol/L) Male 19,52 ± 8.06 16,66 ± 6,98 16,12 ± 6,98
Female 17,19 ± 6,09 14,69 ± 5,91 <0.0012 13,97 ± 5,91 <0.0012
Triglycerides (mmol/L)
median (25th and 75th percentile)
Male 1,64
(1,16–2,4)
1,69
(1,26–2,27)
1,7
(1,26–2,25)
Female 1,44
(1,04–2,01)
1,73
(1,3–2,34)
<0.0123 1,75
(1,31–2,46)
n.s.3
1analysis of variance adjusted for gender only
2analysis of variance adjusted for age and gender
3analysis of variance additionally adjusted for use of lipid-lowering drugs
4logistic regression, adjusted for age and genderBMC Medical Genetics 2009, 10:36 http://www.biomedcentral.com/1471-2350/10/36
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it might be possible to detect an association between
HMOX1 genotypes and serum levels. However, we were
not able to find any significant association between
HMOX1 genotypes and serum levels of bilirubin (e.g. -
413A>T and bilirubin (μmol/L): AA 10.78 ± 6.50, AT
11.12 ± 6.67, and TT 10.95 ± 5.99, means ± standard devi-
ations) or iron, even after adjustment for age, gender, or
other cardiovascular risk factors.
Previously a correlation of lipid parameters and the (GT)n
repeat has been published [29]. To avoid a confounding
by lipid lowering drugs we analyzed only those patients (n
= 1648) not receiving lipid lowering therapy. We found a
significant increase of HDL-C (mmol/L) only for homozy-
gote carriers of the 29-A haplotype (0 – 1.02 ± 0.28, 1 –
1.03 ± 0.29, 2 – 1.08 ± 0.05, means ± standard devia-
tions), which was robust against adjustment for age and
gender (p = 0.006), but no association with LDL-C or trig-
lycerides.
Discussion
The presented data show in a prospective case-control
study of more than 3000 participants that neither the
(GT)n  dinucleotide repeat nor the -413A>T polymor-
phism in the HMOX1 promoter are associated with angi-
ographic CAD, MI or survival rate in Caucasians
undergoing coronary angiography.
The functional relevance of both variants in the HMOX1
promoter is still under debate. Yamada et al. described a
higher response of reporter gene constructs with short
(GT) repeats to H202 exposure in A549 and Hep3B cell
[30]. Similar results were obtained by analyzing HO-1
mRNA and activity in lymphoblastoid cell lines from sub-
jects homozygous for small or long repeats [31] or by ana-
lyzing the HO-1 expression in mononuclear cells from
patients who underwent coronary angiography [24]. In all
studies the short repeats were associated with a higher
expression rate. However, Ono et al. [21,32] showed by in
vitro experiments with reporter gene constructs that the
Table 2: Prevalence of HMOX1 genotypes and haplotypes in 
CAD patients and controls.
HMOX1 genotype Controls CAD P1
N%N%
A>T rs2071746
A A 2 4 63 5 . 58 9 33 5 . 4
A T 3 4 1 4 9 . 21 1 8 14 6 . 8
TT 106 15.3 452 17.9 0.245
A allele 833 60.1 2967 58.7
T allele 553 39.9 2085 41.3 0.358
VNTR S <25, L ≥ 25 repeats
SS 66 9.5 286 11.3
S L 3 0 2 4 3 . 61 0 7 04 2 . 4
L L 3 2 5 4 6 . 91 1 7 04 6 . 30 . 3 9 9
S allele 434 31.3 1642 32.5
L allele 952 68.7 3410 67.5 0.402
VNTR S <27, L ≥ 27 repeats
SS 93 13.4 370 14.6
S L 3 2 8 4 7 . 31 1 5 74 5 . 8
LL 272 39.2 999 39.5 0.651
S allele 514 37.1 1897 37.5
L allele 872 62.9 3155 62.5 0.752
Haplotype 22-T
0 455 65.7 1631 64.6
1 209 30.2 774 30.6
2 29 4.2 121 4.8 0.752
other haplotypes 1119 80.7 4036 79.9
22 – T 267 19.3 1016 20.1 0.484
Haplotype 29 – A
0 185 26.7 718 28.4
1 356 51.4 1243 49.2
2 152 21.9 565 22.4 0.566
other haplotypes 726 52.4 2679 53.0
29 – A 660 47.6 2373 47.0 0.669
1 Chi-squaredtest
Table 2: Prevalence of HMOX1 genotypes and haplotypes in 
CAD patients and controls. (Continued)BMC Medical Genetics 2009, 10:36 http://www.biomedcentral.com/1471-2350/10/36
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length of the (GT)n repeat did not influence the activity of
the HMOX1 promoter in bovine aortic endothelial cells.
They found that – instead of the (GT)n  repeat – the
responsible element was an A>T exchange at position -
413, giving rise to a 4-fold increase of activity. Therefore
further experiments are required to clear the functionality
of these variants.
Irrespective of the unclear functional role there are several
reports suggesting a role of the (GT)n  repeat in the
HMOX1  promoter in cardiovascular disease. Asian
patients with a lower number of repeats were less suscep-
tible to pulmonary emphysema and coronary artery dis-
ease [17,18,30]. Further, a lower number of repeats was
associated with a lower restenosis rate after balloon dila-
tation in the femoral artery [15] suggesting a protective
effect on restenosis. In support of this hypothesis, long
repeats have been related to in-stent-restenosis after per-
cutanous coronary intervention [20,22]. However, data of
Wijpkema et al. [33], who followed a group of about
3.000 patients for 10 months after successful percutanous
coronary intervention, did not confirm the previous
observations. Recently, the results of Wijpkema at el. have
been confirmed by Tiroch et al, who studied 1357 patients
6 months after coronary stenting [34]. Like these two
groups and in contrast to several smaller studies, we have
not been able to confirm any influence of the (GT)n mic-
rosatellite in the promoter of the HMOX1 gene on the risk
of CAD, a history of MI, and total or cardiovascular mor-
tality.
It is not unusual, that association studies of genetic poly-
morphisms produce divergent results, especially if small
numbers of cases and controls are examined. In many
instances positive associations seen in small studies have
been disproven in subsequent studies of larger cohorts.
Both, our CAD and control group were substantially larger
than the groups investigated in the other reports. The only
report with a comparable number of participants is the
study of Wijpkema et al. and their results are in line with
ours [33]. In addition, the reliability of the former studies
is challenged by the creation of three subclasses
[17,30,31] or different cut-offs like S<23 [17], S<25
[15,23], S<26 [20,24], S<27 [18], and S<29 [22] without
any rational explanation for these classifications. Espe-
cially in small cohorts the cut-off can substantially affect
risk estimation. To avoid this problem we examined two
common cut-offs (S<25 and S<27), with the minor allele
representing 32.2% or 37.5%, respectively, and found no
association with cardiovascular disease, irrespective of the
chosen model. Therefore, we are confident that previous
observations have overestimated the effect of the (GT)n
repeat.
Concerning the -413A>T SNP only one study has been
published before [21] showing a decreased risk of
ischemic heart disease for homozygous carriers of the A
allele in Japanese individuals. First, we found a switch in
the allele distribution in Caucasians towards A as the
major allele (A = 0,589 versus A = 0,442 in Japanese), con-
firming data of the HapMap consortium for Caucasians,
Table 3: Odds ratios (OR) for angiographic CAD according to HMOX1 genotypes and haplotypes.
Model 1
OR (95% CI)
P Model 2
OR (95% CI)
P Model 3
OR (95% CI)
P
A>T rs2071746
AA 1.0reference 1.0reference 1.0reference
AT 0.95 (0.79–1.15) 0.619 0.92 (0.76–1.12) 0.398 1.03 (0.82–1.30) 0.788
TT 1.18 (0.91–1.52) 0.215 1.16 (0.89–1.52) 0.282 1.27 (0.93–1.73) 0.142
AA vs AT vs TT2 1.06 (0.94–1.19) 0.363 1.04 (0.92–1.19) 0.506 1.11 (0.95–1.28) 0.190
AA vs AT or TT1 1.21 (0.96–1.52) 0.110 1.22 (0.95–1.55) 0.115 1.24 (0.94–1.65) 0.135
AA or AT vs TT1 1.01 (0.84–1.20) 0.963 0.98 (0.81–1.17) 0.789 1.09 (0.88–1.35) 0.455
VNTR S<25, L ≥ 25
SS 1.0reference 1.0reference 1.0reference
SL1 0.82 (0.61–1.10) 0.183 0.76 (0.56–1.05) 0.086 0.70 (0.49–1.019 0.056
LL1 0.83 (0.62–1.12) 0.217 0.80 (0.59–1.09) 0.153 0.71 (0.49–1.02) 0.063
SS vs SL vs LL2 0.95 (0.84–1.08) 0.407 0.95 (0.83–1.09) 0.413 0.90 (0.77–1.05) 0.187
SS vs SL or LL1 0.82 (0.62–1.09) 0.180 0.78 (0.58–1.05) 0.100 0.71 (0.50–1.00) 0.049
SS or SL vs LL1 0.98 (0.83–1.16) 0.787 0.99 (0.83–1.19) 0.945 0.95 (0.77–1.16) 0.592
1Genotypes treated as categorical variables and compared to the reference category.
2Genotypes treated as interval-scaled variables.
Model 1: unadjusted.
Model 2: adjusted for age, and sex.
Model 3: in addition adjusted for clinical status at presentation (no CAD, stable CAD, unstable CAD, NSTEMI, STEMI), body mass index, metabolic 
syndrome/diabetes mellitus, hypertension, smoking, LDL cholesterol, HDL cholesterol, triglycerides (log transformed), SAA, use of betablockers, 
use of lipid lowering drugs.BMC Medical Genetics 2009, 10:36 http://www.biomedcentral.com/1471-2350/10/36
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and second we could not confirm any of the described
associations. This is not unusual because it is well known
that there is a significant genetic diversity between Cauca-
sians and Asians. Furthermore the number of cases in the
Japanese study was very low (MI = 393, angina pectoris =
204) [21].
On product of the enzymatic action of HO-1 is biliverdin,
which in turn is converted to bilirubin. Biliverdin and
bilirubin are both antioxidants, and higher serum levels
of bilirubin are inversely related to the risk of CAD [14].
Actually, a similar relationship can be found in our study,
the control group showing significantly higher serum lev-
els of bilirubin (Table 1). In contrast to the hypothesis
that genetic variants of HMOX1 associated with a higher
expression would increase bilirubin serum levels we did
not see any association between HMOX1 genotypes and
bilirubin concentration. We can not exclude that other
genes involved in bilirubin metabolism superpose the
effect of different HMOX1 genotypes. One candidate gene
is UGT1A1, coding for bilirubin uridine diphosphate-glu-
curonosyltransferase. This enzyme is responsible for the
glucuronidation of bilirubin and thus enhances its elimi-
nation. Recently, a promoter variation (UGT1A1*28) has
been associated with higher bilirubin serum levels and
lower risk for coronary heart disease in the Framingham
Heart Study [35]. The metabolism of iron is even more
complicated and therefore it is not surprising that we did
not see any correlation between HMOX1 genotypes and
serum iron levels.
A methodological aspect of the present study that deserves
discussion, like in many case-control association studies,
is the appropriateness of the control group. Because angi-
ography is relatively insensitive for early lesions that do
not impact on the vascular lumen, early lesions undetect-
able by angiography could not be ruled out in controls,
similar to coronary microvascular dysfunction. Nonethe-
less, coronary angiography remains a gold standard for
the diagnosis of CAD, and for the definition of the coro-
nary artery status, this may however be regarded as a
strength of the study because of "controls" were also stud-
ied by angiography. This is crucial because the prevalence
of clinically asymptomatic coronary atherosclerosis has
been reported to be high at or above the age of 50 years
[36]. Hence, angiography based recruitment of controls
rules out that individuals with significant, yet clinically
unapparent CAD are inadvertently allocated in the control
group. Surprisingly, our control group appears well repre-
sentative since the major cardiovascular risk factors occur
at a similar frequency as in the general population [37].
Conclusion
In conclusion, the regulation of the HMOX1 gene may be
determined, at least in part, by genetics, and reduced abil-
ity to induce HO-1 expression may be involved in the
mechanism of coronary atherosclerosis. Nevertheless, nei-
ther the (GT)n dinucleotide repeat nor the -413A>T poly-
morphism of HMOX1 gene are reliable genetic markers
for cardiovascular disease in Caucasians.
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